Pharmacological inhibition of JAK1/2 with ruxolitinib has shown antileukemic efficacy in primary xenograft models of ETP-ALL, both in the presence and absence of JAK–STAT mutations, and it has been reported to counteract IL-7-induced hyperactivation [98,99]. Here, JAK1 is linked to acute lymphoblastic leukemia.